Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans

This study is for veterans aged 50 to 85 who have experienced a mild traumatic brain injury (mTBI). Researchers are looking at how two types of training—Alpha neurofeedback training and Visual Attention Training—might improve thinking skills. Alpha neurofeedback training helps you learn to control your brainwaves, while Visual Attention Training involves practicing tasks that improve your focus. The goal is to see if these trainings can improve specific areas of cognitive function (thinking abilities) after 6 weeks. The study plans to enroll 36 participants, but its current status is unclear.

Study design: This interventional study plans to enroll 36 participants. It is not specified if it is randomized or blinded.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: The primary cognitive function outcomes will be measured at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans

Active, Not Recruiting

NAAges 50–85InterventionalTreatment

University of Alabama at Birmingham

~36 participants

Updated 2026-08-07 on ClinicalTrials.gov

What's tested:Alpha neurofeedback trainingVisual Attention Training

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Specific domains of cognitive function

Measured over 6 weeks

Conditions

Traumatic Brain Injury

Mild Traumatic Brain Injury

Aging

Cognitive Decline

NCT06217575

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

CH19 933 19th St S
Birmingham, Alabamano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

English speaking

Veterans with mild traumatic brain injury (mTBI):

A history of mTBI confirmed by the Ohio State University TBI Identification Method-Short Form (including a requirement that the mTBI caused a loss of consciousness lasting less than 30 min).

An additional note will be made for Veterans with mTBI with a report of objective or subjective cognitive decline not meeting the criteria (i.e.- Montreal Cognitive Assessment (MoCA) \>23) for impairment

Exclusion

Metal of foreign objects in the body that would interfere with an magnetic resonance imaging (MRI) or transcranial magnetic stimulations (TMS)

History of penetrating head wounds or a diagnosis of moderate/severe TBI

Participants with significant visual field deficits were excluded, as were those with active suicidal ideation

Suicidal ideation will be assessed with the Columbia suicidality scale (C-SSRS)

Participants with active ideation will be referred to the Veteran Crisis Line (988) (or walked) to the Front Door program at the Birmingham East clinic

Participation in a concurrent clinical trial that could affect study outcome (however, participation in standard treatments e.g. occupational therapy or use of prescribed medications such as antidepressants is acceptable)

Smoker \> 1 pack per day

Significant cognitive impairment defined as \<23 on Montreal Cognitive Assessment (MoCA) or diagnosis of mild cognitive impairment or dementia

Visual (corrected acuity \<20/80) and motor capacity (completion of 9-hole pegboard) to use a computerized intervention

In-patient status

Severe visual impairment, which would preclude completion of the assessments

Progressive, degenerative neurologic disease, e.g., Parkinsons Disease, multiple sclerosis

Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement Actively taking GABAergic agonist/antagonist medication (benzodiazepines, gabapentin, etc.)

Terminal illness with a life expectancy of less than 12 months, as determined by a physician

Other significant co-morbid diseases that would impair the ability to participate, e.g. renal failure on hemodialysis, severe psychiatric disorder (e.g. bipolar disorder, schizophrenia), heavy alcohol use (\>15 drinks per week); persons with depression will not be excluded

Unable to communicate because of severe hearing loss, speech disorder or language barrier

What this trial measures

Specific domains of cognitive function6 weeks
Measured through composite scores: Executive function/mental flexibility will be measured with the Trail Making Tests, Part A and Part B. The results for both TMT-A and TMT-B are reported as the number of seconds required to complete a task. Processing speed (using the Digit Symbol Substitution Test) will be measured as the total correct number-symbol matches achieved in 90 seconds. Verbal fluency (semantic, animal naming, and phonemic) will be measured by using the Controlled Oral Word Association Test and assessed through the total number of words identified by category and letter.

Trialytics